

# Psychological mechanisms in suicidal behaviour

<b>Submission date</b> 03/03/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 22/07/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 28/11/2012	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Background and study aims.

This study aimed to examine the acceptability and mechanisms of action of Mindfulness-based Cognitive Therapy (MBCT) delivered to patients in remission, but with a history of serious suicidal thoughts or behaviour. The aim of the study was to explore the feasibility of delivering MBCT to this population, and the extent to which treatment with MBCT could reduce vulnerability to suicidal thoughts and behaviour through an examination of its effects on psychological factors linked to of suicidal vulnerability.

Who can participate?

Participants aged between 18 and 65 who were currently well but reported at least one prior episode of major depression accompanied by serious suicidal thoughts were recruited from general practitioners and local psychologists/psychiatrists and from the community. All participants were required to be well (no more than one week of minimal depressive symptoms in the past 8 weeks), and to have experienced no episodes of mania for at least 6 months. Additional exclusion criteria included current psychosis, obsessive compulsive disorder or eating disorder as their main problem, current deliberate self harm on a regular basis, a neurological disorder or an inability to complete assessments due to language difficulties or cognitive impairment.

What does the study involve?

Participants were interviewed using the Mini International Neuropsychiatric Interview to establish psychiatric history. Following this, participants completed a number of other assessment measures assessing aspects of cognitive vulnerability to depression and suicidality. These measures included assessment of residual symptoms of depression, mood-related impairments in problem solving and future thinking, autobiographical memory deficits, tendency to suppress unwanted thoughts and self-discrepancy (perceptions of distance between how one currently sees themselves and how one would like to be). Participants were then randomly allocated to either immediate treatment with MBCT or a waitlist condition. The measures were completed again at the end of treatment or waitlist phase. Following this the waitlist group received treatment with MBCT.

What are the possible benefits and risks of participating?

Benefits included the fact that all participants were offered treatment with Mindfulness Based Cognitive Therapy, either immediately or at the end of the waitlist phase of the study. Potential

risks to participants related to the distress of reporting on prior psychiatric history and the inherent challenges of engaging in a therapeutic process designed to target vulnerability to recurrent depression and suicidality.

Where is the study run from?

Department of Psychiatry, University of Oxford

When is the study starting and how long is it expected to run for?

The study started in May 2005 and ended in December 2005

Who is funding the study?

The Wellcome Trust

Who is the main contact?

Professor Mark Williams

mark.williams@psych.ox.ac.uk

## Contact information

**Type(s)**

Scientific

**Contact name**

Prof J. Mark G. Williams

**Contact details**

Oxford University

Department of Psychiatry

Warneford Hospital

Oxford

United Kingdom

OX3 7JX

+44 (0)1865 226445

mark.williams@psych.ox.ac.uk

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**

PRG/06/01

## Study information

**Scientific Title**

**Study objectives**

This is a preliminary (explanatory) trial to assess the immediate effects of Mindfulness-based Cognitive Therapy (MBCT) on cognitive reactivity (the tendency to react to small changes in mood with a catastrophic and rapidly escalating pattern of suicidal thinking).

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Other

**Study type(s)**

Treatment

**Participant information sheet****Health condition(s) or problem(s) studied**

Suicidality

**Interventions**

Treatment:

Mindfulness-Based Cognitive Therapy (MBCT): manualised, eight week treatment combining stress reduction techniques and cognitive therapy and Treatment As Usual (TAU)

Control:

Waiting List control and Treatment As Usual (TAU)

**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome measure**

1. Depression
2. Frequency of thought suppression
3. Change in problem solving and future thinking following experimental induction of mood
4. Self-rated mindfulness

5. Discrepancy between actual and ideal self-guides
6. Specificity of autobiographical memory

**Secondary outcome measures**

No secondary outcome measures

**Overall study start date**

01/05/2005

**Completion date**

01/12/2005

## **Eligibility**

**Key inclusion criteria**

1. Aged 18 to 64
2. History of major depression with suicidal ideation and/or suicidal behaviour
3. Not currently depressed or suicidal (at least eight weeks symptom free)

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

12

**Key exclusion criteria**

1. Visually impaired
2. Not fluent in English
3. Habitual self-damaging acts
4. Bipolar disorder
5. Schizophrenia
6. Active substance abuse
7. Eating disorder
8. Primary Obsessive Compulsive Disorder (OCD)

**Date of first enrolment**

01/05/2005

**Date of final enrolment**

01/12/2005

# Locations

## Countries of recruitment

England

United Kingdom

## Study participating centre

**Oxford University**

Oxford

United Kingdom

OX3 7JX

# Sponsor information

## Organisation

University of Oxford (UK)

## Sponsor details

University Offices

Wellington Square

Oxford

England

United Kingdom

OX1 2JD

+44 (0)1865 270143

researchservices@admin.ox.ac.uk

## Sponsor type

University/education

## Website

<http://www.ox.ac.uk/>

## ROR

<https://ror.org/052gg0110>

# Funder(s)

## Funder type

Charity

**Funder Name**

The Wellcome Trust (UK) (grant ref: 067797)

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	preliminary results	01/04/2008		Yes	No
<a href="#">Results article</a>	results	01/12/2008		Yes	No
<a href="#">Results article</a>	results	01/06/2009		Yes	No